Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
ENvue Medical, Inc. incurred guarantee of all obligations and liabilities of ENvue under the Note with Alpha Capital Anstalt at not specified maturing not specified.
- Instrument
- guarantee
- Principal
- all obligations and liabilities of ENvue under the Note
- Counterparty
- Alpha Capital Anstalt
- Rate
- not specified
- Maturity
- not specified
- Event
- incurrence
Exact text from the filing
In connection with ENvue’s issuance of the Note, on April 11, 2025, the Company entered into that certain Guaranty (the “ Guaranty ”) in favor of the Lender, pursuant to which the Company has agreed to guarantee to the Lender the payment of all obligations and liabilities of ENvue under the Note, including, without limitation, for principal, interest and any other amounts due and payable by ENvue under the Note (the “ Guaranteed Obligations ”).
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.95
ENvue Medical, Inc. incurred loan of $360,000 with Alpha Capital Anstalt at 8.0% per annum maturing June 11, 2025.
- Instrument
- loan
- Principal
- $360,000
- Counterparty
- Alpha Capital Anstalt
- Rate
- 8.0% per annum
- Maturity
- June 11, 2025
- Event
- incurrence
Exact text from the filing
On April 11, 2025, ENvue Medical Holdings, Corp. (“ ENvue ”), a wholly-owned subsidiary of NanoVibronix, Inc. (the “ Company ”), issued a promissory note (the “ Note ”) to Alpha Capital Anstalt (the “ Lender ”) in the principal amount of $360,000 (the “ Principal Amount ”), together with all accrued interest thereon.
View on SEC.gov